XERS
Xeris Pharmaceuticals Inc
8.80$
+7.3%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 0.7% | 0.3% | 1.7% | 58.9% | 58.9% | 26.9% | 20.5% | 17.5% | 18.1% | 18.3% | |
| 99.3% | 99.7% | 98.3% | 41.1% | 41.1% | 73.1% | 79.5% | 82.5% | 81.9% | 81.7% | |
| 952.4% | 1,296.0% | 1,649.2% | 2,220.4% | 2,220.4% | 50.7% | 19.0% | 13.6% | 12.6% | 10.7% | |
| 377.7% | 515.1% | 856.5% | 2,316.7% | 2,708.7% | 253.5% | 124.9% | 89.1% | 80.5% | 62.5% | |
| 1,330.0% | 1,811.1% | 2,505.8% | 4,537.1% | 4,537.1% | 305.4% | 153.8% | 109.4% | 98.4% | 73.2% | |
| -1,230.8% | -1,711.4% | -2,407.5% | -4,496.0% | -4,496.0% | -232.2% | -74.3% | -26.8% | -16.6% | 8.5% | |
| 0.2% | 0.1% | 103.2% | 263.2% | 263.2% | 14.5% | 12.8% | 16.2% | 16.3% | 10.0% | |
| -1,228.7% | -1,706.6% | -2,437.3% | -4,630.3% | -4,630.3% | -247.5% | -87.2% | -38.7% | -28.1% | 0.2% | |
| -0.3% | 0.1% | 73.4% | -16.8% | -16.8% | -0.2% | -1.3% | -0.8% | -1.1% | – | |
| -1,228.7% | -1,706.6% | -2,437.3% | -4,613.5% | -4,613.5% | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% | |
| -1,217.8% | -1,695.2% | -2,321.1% | -4,392.6% | -4,327.6% | -229.2% | -62.9% | -14.5% | -6.9% | 4.4% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.